AMER3

Summary

AMER3 (APC membrane recruitment protein 3, HGNC:26771) is a protein-coding gene on chromosome 2q21.1, encoding APC membrane recruitment protein 3 (Q8N944). Regulator of the canonical Wnt signaling pathway.

Predicted to enable beta-catenin binding activity and phosphatidylinositol-4,5-bisphosphate binding activity. Predicted to be involved in regulation of canonical Wnt signaling pathway. Predicted to be active in plasma membrane.

Source: NCBI Gene 205147 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 205 total — 1 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_152698

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26771
Approved symbol	AMER3
Name	APC membrane recruitment protein 3
Location	2q21.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38377
Ensembl gene	ENSG00000178171
Ensembl biotype	protein_coding
Entrez	205147

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000321420, ENST00000431758, ENST00000458606

RefSeq mRNA: 4 — MANE Select: NM_152698 NM_001105193, NM_001105194, NM_001105195, NM_152698

CCDS: CCDS2164

Canonical transcript exons

ENST00000321420 — 2 exons

Exon	Start	End
ENSE00001281884	130755540	130755674
ENSE00001281894	130762054	130768134

Expression profiles

Bgee: expression breadth broad, 66 present calls, max score 80.67.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8423 / max 94.7987, expressed in 145 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
22517	0.4475	113
22522	0.1592	80
22521	0.0974	59
22520	0.0508	24
22519	0.0503	31
22518	0.0370	15

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	80.67	gold quality
cerebellar cortex	UBERON:0002129	79.80	gold quality
cerebellar hemisphere	UBERON:0002245	79.71	gold quality
middle temporal gyrus	UBERON:0002771	79.57	gold quality
right hemisphere of cerebellum	UBERON:0014890	79.45	gold quality
cerebellum	UBERON:0002037	79.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.58	gold quality
endothelial cell	CL:0000115	77.38	silver quality
buccal mucosa cell	CL:0002336	76.64	gold quality
Brodmann (1909) area 23	UBERON:0013554	74.87	gold quality
prefrontal cortex	UBERON:0000451	74.30	gold quality
primary visual cortex	UBERON:0002436	73.58	gold quality
islet of Langerhans	UBERON:0000006	73.18	gold quality
Brodmann (1909) area 9	UBERON:0013540	73.12	gold quality
frontal cortex	UBERON:0001870	72.97	gold quality
right frontal lobe	UBERON:0002810	72.79	gold quality
tendon of biceps brachii	UBERON:0008188	72.75	gold quality
neocortex	UBERON:0001950	72.12	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	72.12	gold quality
superior frontal gyrus	UBERON:0002661	71.05	gold quality
left ventricle myocardium	UBERON:0006566	71.04	gold quality
cardiac muscle of right atrium	UBERON:0003379	70.79	gold quality
cerebral cortex	UBERON:0000956	70.34	gold quality
occipital lobe	UBERON:0002021	69.85	gold quality
entorhinal cortex	UBERON:0002728	69.31	gold quality
anterior cingulate cortex	UBERON:0009835	69.18	gold quality
myocardium	UBERON:0002349	69.17	gold quality
ganglionic eminence	UBERON:0004023	69.08	gold quality
brain	UBERON:0000955	68.52	gold quality
postcentral gyrus	UBERON:0002581	67.90	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-7303	no	528.91
E-ANND-3	no	2.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

125 targeting AMER3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-590-3P	99.96	74.34	6478
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-7845-5P	99.88	64.88	771

Literature-anchored findings (GeneRIF, showing 1)

• Data suggest Amer3 activates Wnt signaling, in contrast to Amer1/Amer2 which inhibit Wnt, suggesting non-redundant role of Amer proteins in regulation of Wnt pathway. Knockdown of Amer3 reduces Wnt target gene expression in colorectal cancer cells. (PMID:24251807)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	amer3	ENSDARG00000095819
mus_musculus	Amer3	ENSMUSG00000045174
rattus_norvegicus	Amer3	ENSRNOG00000023603

Paralogs (2): AMER2 (ENSG00000165566), AMER1 (ENSG00000184675)

Protein

Protein identifiers

APC membrane recruitment protein 3 — Q8N944 (reviewed: Q8N944)

Alternative names: Protein FAM123C

All UniProt accessions (3): Q8N944, C9J4B8, C9JS07

UniProt curated annotations — full annotation on UniProt →

Function. Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane.

Subcellular location. Cell membrane.

Similarity. Belongs to the Amer family.

RefSeq proteins (4): NP_001098663, NP_001098664, NP_001098665, NP_689911* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019003	AMER	Family

Pfam: PF09422

UniProt features (16 total): region of interest 8, compositionally biased region 6, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N944-F1	45.30	0.01

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 50 (showing top): GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, NRSF_01, GOCC_NUCLEAR_BODY, GOMF_BETA_CATENIN_BINDING, GOMF_PHOSPHATIDYLINOSITOL_4_5_BISPHOSPHATE_BINDING, GOMF_PHOSPHATIDYLINOSITOL_PHOSPHATE_BINDING, GOMF_PHOSPHATIDYLINOSITOL_BINDING, GOMF_PHOSPHATIDYLINOSITOL_BISPHOSPHATE_BINDING, GOMF_LIPID_BINDING, GOMF_PHOSPHOLIPID_BINDING, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3, MIKKELSEN_MEF_HCP_WITH_H3K27ME3, MARTENS_TRETINOIN_RESPONSE_UP

GO Biological Process (2): Wnt signaling pathway (GO:0016055), regulation of canonical Wnt signaling pathway (GO:0060828)

GO Molecular Function (4): phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), beta-catenin binding (GO:0008013), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cell surface receptor signaling pathway	1
regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
phosphatidylinositol phosphate binding	1
phosphatidylinositol bisphosphate binding	1
protein binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

762 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AMER3	ZNF518B	Q9C0D4	585
AMER3	AMER2	Q8N7J2	533
AMER3	SVOP	Q8N4V2	512
AMER3	ARHGEF4	Q9NR80	488
AMER3	GPR148	Q8TDV2	475
AMER3	REPS2	Q8NFH8	473
AMER3	KLF14	Q8TD94	473
AMER3	PLEKHB2	Q96CS7	455
AMER3	GNPNAT1	Q96EK6	448
AMER3	FAM168B	A1KXE4	430
AMER3	SP6	Q3SY56	430
AMER3	ARHGEF9	O43307	420
AMER3	CTXN2	P0C2S0	417
AMER3	FHL2	Q14192	412
AMER3	TMEM179	Q6ZVK1	411

IntAct

15 interactions, top by confidence:

A	B	Type	Score
AMER3	APC	psi-mi:“MI:0914”(association)	0.630
APC	AMER3	psi-mi:“MI:0915”(physical association)	0.630
AMER3	APC	psi-mi:“MI:0915”(physical association)	0.630
AMER3	APC	psi-mi:“MI:0403”(colocalization)	0.630
AMER1	AMER3	psi-mi:“MI:0915”(physical association)	0.540
AMER1	AMER3	psi-mi:“MI:0403”(colocalization)	0.540
AMER3	AMER1	psi-mi:“MI:0915”(physical association)	0.540
AMER3	AXIN2	psi-mi:“MI:0915”(physical association)	0.500
Axin2	AMER3	psi-mi:“MI:0915”(physical association)	0.400
AMER3	Axin2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (1): AMER3 (Affinity Capture-MS)

ESM2 similar proteins: A0A096LP49, A0A8V8TNH8, A0A8V8TPE2, A2VE02, A5D7I0, A6NDY2, A6NGG8, A6NIJ5, A6NNJ1, A8MXJ8, A8MYA2, B1ASB6, B2RW88, D6RGX4, O60269, P0C7V4, P0C7W8, P0C7W9, P0C7X0, P0DV75, P0DV76, Q2KIS6, Q2NL68, Q3SY00, Q4R736, Q4V8B5, Q5RCQ2, Q5SZB4, Q5VZ46, Q5XIK6, Q658T7, Q66JV7, Q6NS69, Q6PAC4, Q6ZMY3, Q76N32, Q7TSA6, Q7Z591, Q80VW7, Q80X53

Diamond homologs: A4IGN8, E1C2Q8, F1QGH6, F1RDM5, Q6INC4, Q6NS69, Q8CCJ4, Q8N7J2, Q8N944, Q5JTC6, Q7TS75

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

205 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	8
Uncertain significance	171
Likely benign	21
Benign	1

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
625693	GRCh37/hg19 2q21.1(chr2:131487820-132166509)	Pathogenic
152346	GRCh38/hg38 2q21.1(chr2:130720173-131278036)x1	Likely pathogenic
441546	GRCh37/hg19 2q21.1(chr2:131477947-131950529)x1	Likely pathogenic
442575	GRCh37/hg19 2q21.1(chr2:131477947-131975365)x1	Likely pathogenic
442906	GRCh37/hg19 2q21.1(chr2:131477947-131956516)x1	Likely pathogenic
443891	GRCh37/hg19 2q21.1(chr2:131477947-131933576)x1	Likely pathogenic
545243	NC_000002.12:g.(?130725519)(131168548_?)del	Likely pathogenic
625692	GRCh37/hg19 2q21.1(chr2:131486951-131933628)	Likely pathogenic
916554	NM_152698.3(AMER3):c.2236C>T (p.Arg746Ter)	Likely pathogenic

SpliceAI

241 predictions. Top by Δscore:

Variant	Effect	Δscore
2:130762052:A:AG	acceptor_gain	1.0000
2:130762053:G:GG	acceptor_gain	1.0000
2:130755675:G:GG	donor_gain	0.9900
2:130759522:G:T	donor_gain	0.9900
2:130762053:GC:G	acceptor_gain	0.9900
2:130762053:GCA:G	acceptor_gain	0.9900
2:130755673:CA:C	donor_gain	0.9800
2:130762048:CCACA:C	acceptor_loss	0.9800
2:130762049:CACAG:C	acceptor_loss	0.9800
2:130762050:ACAGC:A	acceptor_loss	0.9800
2:130762052:AG:A	acceptor_loss	0.9800
2:130762053:G:A	acceptor_loss	0.9800
2:130762053:GCAGC:G	acceptor_gain	0.9800
2:130755671:CACA:C	donor_gain	0.9700
2:130755672:ACA:A	donor_gain	0.9700
2:130755673:CAGT:C	donor_loss	0.9700
2:130755674:AG:A	donor_loss	0.9700
2:130755675:GT:G	donor_loss	0.9700
2:130755676:TG:T	donor_loss	0.9700
2:130755677:GAG:G	donor_loss	0.9700
2:130755678:AGTA:A	donor_loss	0.9700
2:130759568:G:GT	donor_gain	0.9700
2:130755670:ACACA:A	donor_gain	0.9600
2:130756379:GCG:G	donor_gain	0.9500
2:130762050:A:AG	acceptor_gain	0.9500
2:130762051:C:G	acceptor_gain	0.9500
2:130762056:G:GA	acceptor_gain	0.9500
2:130755691:C:T	donor_gain	0.9400
2:130762055:A:AG	acceptor_gain	0.9400
2:130762054:CAG:C	acceptor_loss	0.9300

AlphaMissense

5560 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:130763219:A:C	S383R	0.994
2:130763221:T:A	S383R	0.994
2:130763221:T:G	S383R	0.994
2:130762802:T:C	F244L	0.992
2:130762804:C:A	F244L	0.992
2:130762804:C:G	F244L	0.992
2:130763591:G:C	G507R	0.990
2:130762097:T:C	F9L	0.988
2:130762099:C:A	F9L	0.988
2:130762099:C:G	F9L	0.988
2:130762832:T:C	F254L	0.988
2:130762834:C:A	F254L	0.988
2:130762834:C:G	F254L	0.988
2:130763534:T:A	W488R	0.988
2:130763534:T:C	W488R	0.988
2:130763536:G:C	W488C	0.987
2:130763536:G:T	W488C	0.987
2:130762484:T:C	F138L	0.986
2:130762486:T:A	F138L	0.986
2:130762486:T:G	F138L	0.986
2:130762524:T:C	I151T	0.986
2:130762799:A:C	S243R	0.986
2:130762801:C:A	S243R	0.986
2:130762801:C:G	S243R	0.986
2:130763577:T:C	L502P	0.986
2:130763553:T:C	L494P	0.985
2:130763568:A:T	D499V	0.985
2:130763598:T:A	V509D	0.984
2:130763545:G:C	K491N	0.983
2:130763545:G:T	K491N	0.983

dbSNP variants (sampled 300 via entrez): RS1000059749 (2:130760972 C>G), RS1000126975 (2:130765853 T>G), RS1000127328 (2:130753614 C>T), RS1000128977 (2:130759842 G>A), RS1000148985 (2:130762890 C>G), RS1000215190 (2:130756045 C>A), RS1000259494 (2:130757155 A>G), RS1000310657 (2:130765624 G>A,T), RS1000569146 (2:130755900 C>T), RS1000596414 (2:130767735 G>A,T), RS1000607451 (2:130762357 C>A,T), RS1000698447 (2:130757370 G>T), RS1000837785 (2:130756160 G>A,C), RS1000954658 (2:130756907 A>G,T), RS1001402011 (2:130761656 G>A)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:181500, MIM:189960

GenCC curated gene-disease

Mondo (3): schizophrenia (MONDO:0005090), neurodevelopmental disorder (MONDO:0700092), esophageal atresia/tracheoesophageal fistula (MONDO:0008586)

Orphanet (2): Esophageal atresia (Orphanet:1199), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012046_2	Fasting insulin	1.000000e-07

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
C531835	Esophageal atresia with or without tracheoesophageal fistula (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	decreases expression, increases abundance	1
Copper	decreases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Rotenone	decreases expression	1
Aflatoxin M1	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety